Key result
Ranolazine reduces APD ~30% and decreases cellular arrhythmogenesis in human HCM cardiomyocytes.
Answers are grounded in this paper and cite their sources.
Inhibition of late sodium current with ranolazine or GS-967 reverses electrophysiological and calcium handling abnormalities in human hypertrophic cardiomyopathy cardiomyocytes, highlighting a potential therapeutic target for arrhythmias and diastolic dysfunction.
drive myocardial remodeling since the earliest stages of disease and underlie the development of hypertrophy, diastolic dysfunction and the arrhythmogenic substrate. In conclusion, diastolic dysfunction and arrhythmogenesis in human HCM myocardium are driven by functional alterations at cellular and molecular level that may be targets of innovative therapies.
No takes yet. Share an insight, caveat, or question.
Coppini et al. (2018) conducted a review in Hypertrophic Cardiomyopathy (n=43). Ranolazine vs. Baseline / Control cardiomyocytes was evaluated on Action potential duration (APD) and late Na+ current (INaL). In human hypertrophic cardiomyopathy cardiomyocytes, inhibition of late sodium current with ranolazine reduced action potential duration by approximately 30% and decreased cellular arrhythmogenesis.
Synapse has enriched 10 related papers. Consider them for comparative context: